Regenxbio‘s shares have surged following an upgrade from RBC Capital, who raised their price target to $35 and upgraded the stock to Outperform. Chardan Capital also reiterated a “buy” rating with a price target of $52.00. Analysts are optimistic about Regenxbio’s recent performance, with the average stock forecast for the next year sitting at $35.39, suggesting a potential upside of 110.8%.
This positive outlook has investors excited about Regenxbio’s future prospects as of March 8, 2024.
Regenxbio Inc. (RGNX) Stock Sees Slight Decrease on March 8th, Pre-Market Trading Shows Recovery
On March 8, 2024, the stock performance of Regenxbio Inc. (RGNX) saw a slight decrease in price since the market last closed. According to data from CNN Money, RGNX shares dropped by $0.77, which represents a 3.21% decrease from the previous closing price of $23.23. However, there was a slight recovery in pre-market trading, with the stock rising by $0.44. Despite the drop in price on March 8th, RGNX is still trading in the middle of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been relatively stable over the past year and is currently in a favorable position compared to its long-term trend. Overall, the slight decrease in RGNX stock price on March 8th may be a temporary dip in an otherwise stable performance. Investors should continue to monitor the stock and consider all available information before making any trading decisions.
Regenxbio Inc. (RGNX) Stock Sees Mixed Performances in Latest Financial Results: Revenue Declines but Net Income and EPS Increase
On March 8, 2024, Regenxbio Inc. (RGNX) stock experienced mixed performances as the company released its latest financial results. According to data from CNN Money, the total revenue for RGNX in the past year was $90.24 million, with a significant decrease of 19.94% compared to the previous year. In the fourth quarter, the total revenue was $22.21 million, showing a further decline of 23.18% compared to the previous quarter.
Despite the decrease in total revenue, RGNX managed to increase its net income both annually and quarterly. The net income for the past year was -$263.49 million, which represented a 6.0% increase compared to the previous year. In the fourth quarter, the net income was -$62.89 million, showing a 1.65% increase compared to the previous quarter.
Furthermore, the earnings per share (EPS) for RGNX also saw an increase in both annual and quarterly performances. The EPS for the past year was -$6.02, which indicated a 7.25% increase compared to the previous year. In the fourth quarter, the EPS was -$1.43, showing a 1.53% increase compared to the previous quarter.
Overall, the financial results for RGNX on March 8, 2024, reflected a mixed performance for the company. While there was a significant decline in total revenue, RGNX managed to increase its net income and earnings per share, which could be seen as a positive sign for investors. It will be interesting to see how the company continues to navigate the challenges in the biotechnology sector and whether it can sustain its growth in the future. Investors should closely monitor RGNX stock performances and keep an eye on any new developments from the company.
